Citi raised the firm’s price target on Johnson & Johnson to $213 from $200 and keeps a Buy rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Walmart Stock (WMT) Feeling the Love of the Crowd Once Again
- Johnson & Johnson price target raised to $193 from $172 at Bernstein
- Balanced Outlook on Johnson & Johnson: Strong Performance Amidst Market Challenges Justifies Hold Rating
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer